Android app on Google Play

Notable Analyst Rating Changes 01/15: (VPHM) (BSX) (GMCR) Upgraded; (HL) (ARMH) (AMTD) Downgraded

January 15, 2013 11:00 AM EST Send to a Friend
BofA/Merrill Lynch upgrades ViroPharma (Nasdaq: VPHM) from Neutral to Buy.

Credit Suisse raises Boston Scientific (NYSE: BSX) from Neutral to Outperform.

Deutsche Bank boosts Cliffs Natural Resources (NYSE: CLF) from Hold to Buy, moving its price target from $40 to $48.

Argus lifts Green Mountain Coffee Roasters (NASDAQ: GMCR) from Hold to Buy.

For daily real-time Upgrades go to

Deutsche Bank trims Hecla Mining (NYSE: HL) from Hold to Sell. Click Here for more color.

Morgan Stanley downgrades ARM Holdings (Nasdaq: ARMH) from Overweight to Equalweight and price target of £9.11.

Sterne Agee lowers TD Ameritrade (NYSE: AMTD) from Buy to Neutral with a price target of $19.

JPMorgan cuts US Airways Group (NYSE: LCC) from Overweight to Neutral with a price target of $18.

For daily real-time Downgrades go to

Baird initiates Duke Realty (NYSE: DRE) with a Outperform and price target of $16.

Lazard Capital starts Nektar Therapeutics (Nasdaq: NKTR) at Buy and $15 target.

UBS begins Vantiv (NYSE: VNTV) with a Neutral and price target of $22.

Sterne Agee assumes E*TRADE (Nasdaq: ETFC) at Buy and $11 target.

For daily real-time New Coverage go to

Visit our new Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Credit Suisse, Deutsche Bank, UBS, JPMorgan, Morgan Stanley, Merrill Lynch, Robert W Baird, Bank of America, Lazard, Sterne Agee, Argus, Notable Analyst Rating Changes

Add Your Comment